Evidence map›Paper›PMID 33123120›Full record

ReviewFrontiers in immunology2020

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.

Ya Xu, Yang Fu, Bo Zhu, Jun Wang, Bicheng Zhang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 5 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 5 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Liquid biopsy in bladder cancer: towards precision oncology.Journal of translational medicine · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Ya XuCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Yang FuDepartment of Oncology, Xiangyang Hospital, Hubei University of Chinese Medicine, Xiangyang, China.
Bo ZhuInstitute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, China.
Jun WangDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
Bicheng ZhangCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Renmin Hospital of Wuhan University · CNAffiliated Hospital of Shandong University of Traditional Chinese Medicine · CNXiangyang Hospital of Traditional Chinese Medicine · CNXinqiao Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence and continuous development of immune checkpoint inhibitors (ICIs) therapy brings a revolution in cancer therapy history, but the major hurdle associated with their usage is the concomitant ICIs-related toxicities that present a challenge for oncologists. The toxicities may involve non-specific symptoms of multiple systems as for the unique mechanism of formation, which are not easily distinguishable from traditional toxicities. A few of these adverse events are self-limiting and readily manageable, but others may limit treatment, cause interruption and need to be treated with methylprednisolone or tumor necrosis factor-α (TNF-α) antibody infliximab, and even directly threaten life. Early accurate recognition and adequate management are critical to the patient's prognosis and overall survival (OS). Several biomarkers such as the expression of programmed cell death ligand 1 (PD-L1), tumor mutation burden (TMB), and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) have been proved to be the predictors for anti-tumor efficacy of ICIs, but there is a gap in clinical needs for effective biomarkers that predict toxicities and help filter out the patients who may benefit most from these costly therapies while avoiding major risks of toxicities. Here, we summarize several types of risk factors correlated with ICIs-related toxicities to provide a reference for oncologists to predict the occurrence of ICIs-related toxicities resulting in a timely process in clinical practice.

Indexed as

BiomarkersAnimalsAntineoplastic Agents, ImmunologicalBiomarkers, TumorHumansImmune Checkpoint InhibitorsImmune Checkpoint ProteinsLiquid BiopsyMolecular Targeted TherapyNeoplasmsOrgan SpecificityPrognosisTumor MicroenvironmentAntineoplastic Agents, ImmunologicalBiomarkersBiomarkers, TumorImmune Checkpoint InhibitorsImmune Checkpoint Proteinsimmune checkpoint inhibitorPD-1PD-L1predictive biomarkertoxicity

Identifiers

PMID33123120
PMCPMC7572846
OpenAlexW3092129964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.